Given this opportunity, we developed a quality improvement (QI) intervention to aid the adoption of SGLT2 inhibitors and GLP-1 RAs in patients with T2D and ASCVD, CKD, and/or HF. The gene discussed is SLC5A2; the disease is chronic kidney disease.